Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. Heart (2014) 1.48

Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. J Thromb Thrombolysis (2013) 1.48

Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31

P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 0.97

Percutaneous coronary intervention in the elderly. Nat Rev Cardiol (2010) 0.93

ST Elevation Myocardial Infarction in the elderly. J Geriatr Cardiol (2012) 0.87

Personalized vascular medicine: individualizing drug therapy. Vasc Med (2011) 0.79

Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc (2015) 0.78

Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78

Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proc Intensive Care Cardiovasc Anesth (2012) 0.78

TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther (2011) 0.77

Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wien Klin Wochenschr (2011) 0.77

Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med (2011) 0.76

Cost-effectiveness of oral antiplatelet agents--current and future perspectives. Nat Rev Cardiol (2011) 0.76

Oral antiplatelet therapy in acute coronary syndromes: update 2012. Eur Heart J Acute Cardiovasc Care (2012) 0.75

Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Heart Assoc (2016) 0.75

Towards personalized medicine based on platelet function testing for stent thrombosis patients. Thrombosis (2012) 0.75

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J (2015) 0.75

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. Am J Ther (2015) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Universal definition of myocardial infarction. Circulation (2007) 11.69

Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med (2004) 11.09

Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Universal definition of myocardial infarction. Eur Heart J (2007) 9.04

Universal definition of myocardial infarction. J Am Coll Cardiol (2007) 8.68

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ (2014) 5.88

Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74

One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation (2007) 5.56

Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00

β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92

Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83

Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72

Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation (2003) 4.43

Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32

Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27

Chronic diseases and injuries in India. Lancet (2011) 4.27

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95

Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72

2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68

2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63

Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62

2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56

Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA (2011) 3.56

Risk indexes for exacerbations and hospitalizations due to COPD. Chest (2007) 3.55

Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48

Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol (2002) 3.45

Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med (2003) 3.43

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J (2002) 3.36

Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31